Trafermin (brand name Fiblast), also known as recombinant human basic fibroblast growth factor (rhbFGF), is a recombinant form of human basic fibroblast growth factor (bFGF) which is marketed in Japan as a topical spray for the treatment of skin ulcers.[2][3][1] It is also currently in preregistration for the treatment of periodontitis.[2][4] As a recombinant form of bFGF, trafermin is a potent agonist of the FGFR1, FGFR2, FGFR3, and FGFR4.[5][6] The drug has been marketed in Japan since June 2001.[citation needed]
This protein-related article is a stub. You can help Wikipedia by expanding it.
This dermatologic drug article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 18.190.176.75